Weill Cornell/Rockefeller/Sloan-kettering MST Program

描述（由申请人提供）：三机构MD-PhD计划是威尔康奈尔医学院（WCMC），洛克菲勒大学（RU）和Sloan-Kettering癌症研究所（SKI）的联合事业。它的使命是培训生物医学调查人员，一方面，他们对生物医学科学有深入的了解，掌握当代研究技能，这将使他们能够进行基础研究，阐明与人类疾病有关的基本生物过程;另一方面，在人类生物学、病理学和临床医学方面有很好的基础，这将使他们能够将基础研究的进展转移到对人类疾病的理解，预防和治疗上。这三个机构经营三个研究生院：威尔康奈尔大学医学科学研究生院（WGS），WCMC和SKI之间的联合事业; RU的大卫洛克菲勒研究生院;和SKI的Gerstner生物医学科学研究生院（GSK）。三机构MD-PhD计划成立于1991年，当时两个独立的MD-PhD计划，WCMC-RU计划和WCMC-WGS计划加入，形成了目前的计划。GSK将于2009年7月1日成为该计划的一部分。MSTP学员完成在WMC MD学位的所有要求。他们将在三个研究机构的研究实验室接受博士培训，并从GSK，RU或WGS获得博士学位。接受的学员在医学院开学前的7月初到达。在该计划的前两年，他们完成了医学院课程，参加了两个为MD-PhD学生设计的研究生课程，并在他们进入论文实验室之前完成了三个研究轮换（在三个不同的实验室）。当学生选择一个研究实验室，他们在研究生院注册与他们的论文导师相关联。研究生课程和论文的要求是相似的所有MD/博士生，无论他们被录取的研究生院和学生可以交叉注册，并采取课程的学分在任何研究生院。在他们的研究培训结束后，他们已经捍卫了他们的论文，学生返回完成在WMC他们的临床培训。本申请要求资金继续在35年后的三个机构的MD-PhD培训（前身WMC-RU计划成立于1972年;它于1974年获得NIH资助）。在目前的迭代中，该计划汇集了270多个独立研究实验室的教师。超过250名MD-PhD已经从MD-PhD计划及其前身毕业;目前该计划有110名学生。目前的学员来自56所本科院校。他们的平均GPA为3.77，MCAT综合得分为35.4。95%的毕业生接受研究生临床培训;在完成培训的毕业生中，88%的人在医学院，研究机构或生物技术/制药公司任职。

DESCRIPTION (provided by applicant): The Tri-lnstitutional MD-PhD Program is a joint undertaking of Weill Cornell Medical College (WCMC), The Rockefeller University (RU), and the Sloan-Kettering Institute for Cancer Research (SKI). Its mission is to train biomedical investigators who: on the one hand, have advanced understanding of biomedical science and a mastery of contemporary research skills, which will allow them to undertake fundamental studies to elucidate basic biological processes pertaining to human disease; and, on the other hand, are well grounded in human biology, pathobiology and clinical medicine, which will equip them to transfer advances in basic research to the understanding, prevention, and treatment of human disease. The three institutions operate three graduate schools: Weill Cornell Graduate School of Medical Sciences (WGS), a joint undertaking between WCMC and SKI; the David Rockefeller Graduate School at RU; and the Gerstner Graduate School of Biomedical Sciences (GSK) at SKI. The Tri-lnstitutional MD-PhD Program was formed in 1991, when two independent MD-PhD Programs, the WCMC-RU Program and the WCMC-WGS Program, were joined to form the present program. GSK will become part of the Program on July 1, 2009. MSTP trainees complete all the requirements for the MD degree at WMC. They will get their PhD training in research laboratories in three research institutions and receive their PhD degree from GSK, RU or WGS. Accepted trainees arrive in early July before the start of medical school. During the first two years in the Program they complete their medical school course, take two graduate level courses designed for MD-PhD students, and complete three research rotations (in three different laboratories) before they settle into their thesis laboratory. When the students choose a research laboratory they enroll in the graduate school with which their thesis mentor is associated. The graduate course and thesis requirements are similar for all MD/PhD students, irrespective of the graduate school in which they are matriculated-and the students can cross register and take courses for credit in any of the graduate schools. At the end of their research training, after they have defended their thesis, the students return to complete their clinical training at WMC. The present application requests funds to continue MD-PhD training at the three institutions beyond Year 35 (the predecessor WMC-RU Program was formed in 1972; it received NIH funding in 1974). In its current iteration, the Program brings together faculty in more than 270 independent research laboratories. More than 250 MD-PhDs have graduated from the MD-PhD Program and its predecessors; currently there are 110 students in the Program. The current trainees come from 56 undergraduate schools. Their average GPA is 3.77, the combined MCAT score is 35.4. 95% of the graduates pursue post-graduate clinical training; of the graduates who have completed their training, 88% have appointments in medical schools, research institutes or biotech/pharma.